Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Black Diamond Therapeutics, Inc. - Common Stock (NQ:BDTX)

1.776 -0.044 (-2.43%)
Streaming Delayed Price Updated: 1:02 PM EDT, Jun 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,297,534
Open 1.850
Bid (Size) 1.770 (1,400)
Ask (Size) 1.780 (2,800)
Prev. Close 1.820
Today's Range 1.750 - 1.923
52wk Range 1.780 - 4.940
Shares Outstanding 36,213,654
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Black Diamond Therapeutics Touts Silevertinib Lung Cancer Data, Eyes FDA Path ↗
Black Diamond Therapeutics (NASDAQ:BDTX) is positioning its lead oncology drug candidate, silevertinib, as a potential treatment for non-small cell lung cancer patients with non-classical EGFR... 
Via MarketBeat
News headline image
What's Going On With Black Diamond Therapeutics Stock Tuesday? ↗
Black Diamond Therapeutics (NASDAQ: BDTX) stock climbs. Get the latest technical analysis, moving averages, and price action. 
Via Benzinga

Performance

YTD
-28.7%
-28.7%
1 Month
-37.3%
-37.3%
3 Month
-16.6%
-16.6%
6 Month
-35.7%
-35.7%
1 Year
-25.1%
-25.1%

More News

Read More
Which stocks are experiencing notable movement on Friday? ↗
Via Chartmill
Keep an eye on the top gainers and losers in Friday's session. ↗
Via Chartmill
Friday's session: gap up and gap down stocks ↗
Via Chartmill
News headline image
Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
News headline image
Black Diamond Therapeutics Lung Cancer Drug Shows 15.2-Month PFS in Phase 2 Study ↗
Via MarketBeat
News headline image
Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
News headline image
Black Diamond Therapeutics to Host Webcast for Investors Highlighting Updated Results from Phase 2 Trial of Silevertinib in 1L EGFRm NSCLC
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
News headline image
Black Diamond Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
News headline image
Black Diamond Therapeutics Announces Oral Presentation of Silevertinib Phase 2 Data in Frontline EGFRm NSCLC Patients at the 2026 ASCO Annual Meeting
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
News headline image
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
News headline image
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
News headline image
Black Diamond Therapeutics Announces Preliminary Phase 2 Data for Silevertinib in 1L NSCLC and Plans for a Phase 2 Trial of Silevertinib in GBM
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
News headline image
Black Diamond Therapeutics to Host Webcast Presentation Highlighting Silevertinib Phase 2 Clinical Trial Results and Program Update
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
News headline image
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
News headline image
Black Diamond Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
News headline image
4 Biotechnology Stocks Lead Momentum Gains Amid Strong Technicals ↗
Via Benzinga
News headline image
Black Diamond (BDTX) Q2 Loss Narrows 47% ↗
Via The Motley Fool
News headline image
Black Diamond Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
News headline image
Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
News headline image
Black Diamond Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
News headline image
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
From Black Diamond Therapeutics, Inc
Via GlobeNewswire
News headline image
These stocks have an unusual volume in today's session ↗
Via Chartmill
News headline image
Unusual volume stocks in Thursday's session ↗
Via Chartmill

Frequently Asked Questions

Is Black Diamond Therapeutics, Inc. - Common Stock publicly traded?
Yes, Black Diamond Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Black Diamond Therapeutics, Inc. - Common Stock trade on?
Black Diamond Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Black Diamond Therapeutics, Inc. - Common Stock?
The ticker symbol for Black Diamond Therapeutics, Inc. - Common Stock is BDTX on the Nasdaq Stock Market
What is the current price of Black Diamond Therapeutics, Inc. - Common Stock?
The current price of Black Diamond Therapeutics, Inc. - Common Stock is 1.776
When was Black Diamond Therapeutics, Inc. - Common Stock last traded?
The last trade of Black Diamond Therapeutics, Inc. - Common Stock was at 06/12/26 01:02 PM ET
What is the market capitalization of Black Diamond Therapeutics, Inc. - Common Stock?
The market capitalization of Black Diamond Therapeutics, Inc. - Common Stock is 64.30M
How many shares of Black Diamond Therapeutics, Inc. - Common Stock are outstanding?
Black Diamond Therapeutics, Inc. - Common Stock has 64M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.